Fabio Mirabella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabio Mirabella has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Gareth John Morgan
Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
9 shared publications - Faith E. Davies
Perlmutter Cancer Center, NYU Langone Health, New York, NY
7 shared publications - Brian A. Walker
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
6 shared publications - Christopher Paul Wardell
Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
4 shared publications - Lauren I. Aronson
The Institute of Cancer Research, London, United Kingdom
4 shared publications - David C. Johnson
Division of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK
3 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by IOP Publishing in Journal of Physics: Photonics
- Vol. 8 (2)
Unsupervised classification from defocused holographic images for label-free HEK293 cell culture viability assessment
Defocused digital holography, as a label-free, cost-effective and robust phase imaging technique, has the potential to monitor crucial bioproduction process parameters without incurring a major increase in manufacturing costs. In this paper, we present an automatic off-line image processing pipeline from trilambda hologram reconstruction to concentration and viability estimates of HEK293 cell cultures close to Vi-Cell measurements without relying on single-cell labels. The algorithmic chain, that combines supervised and unsupervised learning, is shown to generalize to several HEK293 cell clones and time points without requiring any parameter tuning. Furthermore, image feature spaces derived from one experiment effectively transfer to independent cultures, which enables direct predictions. While phase images reconstructed from single-wavelength holograms did not significantly improve viability or density estimation compared to single wavelength holograms, the RGB approach resulted in more discriminative feature representations and improved clustering. Finally, we showed that extracting only the 50\% most critical image features only leads to a slight degradation of results.
- 2 June 2026
- Published by IOP Publishing in Journal of Physics: Photonics
- Vol. 8 (2)
Open AccessUnsupervised classification from defocused holographic images for label-free HEK293 cell culture viability assessment
Defocused digital holography, as a label-free, cost-effective and robust phase imaging technique, has the potential to monitor crucial bioproduction process parameters without incurring a major increase in manufacturing costs. In this paper, we present an automatic off-line image processing pipeline from trilambda hologram reconstruction to concentration and viability estimates of HEK293 cell cultures close to Vi-Cell measurements without relying on single-cell labels. The algorithmic chain, that combines supervised and unsupervised learning, is shown to generalize to several HEK293 cell clones and time points without requiring any parameter tuning. Furthermore, image feature spaces derived from one experiment effectively transfer to independent cultures, which enables direct predictions. While phase images reconstructed from single-wavelength holograms did not significantly improve viability or density estimation compared to single wavelength holograms, the RGB approach resulted in more discriminative feature representations and improved clustering. Finally, we showed that extracting only the 50\% most critical image features only leads to a slight degradation of results.
- Open Access
- 21 December 2018
- Published by Springer Nature in Blood Cancer Journal
- Vol. 9 (1) , 1
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) genome-wide association study (GWAS) data sets, totalling 11,734 cases and 29,468 controls. A significant genetic correlation between these two B-cell malignancies was shown (Rg = 0.4, P = 0.0046). Furthermore, four of the 45 known CLL risk loci were shown to associate with MM risk and five of the 23 known MM risk loci associate with CLL risk. By integrating eQTL, Hi-C and ChIP-seq data, we show that these pleiotropic risk loci are enriched for B-cell regulatory elements and implicate B-cell developmental genes. These data identify shared biological pathways influencing the development of CLL and, MM and further our understanding of the aetiological basis of these B-cell malignancies.
- 21 December 2018
- Published by Springer Nature in Blood Cancer Journal
- Vol. 9 (1) , 1
Open AccessGenetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) genome-wide association study (GWAS) data sets, totalling 11,734 cases and 29,468 controls. A significant genetic correlation between these two B-cell malignancies was shown (Rg = 0.4, P = 0.0046). Furthermore, four of the 45 known CLL risk loci were shown to associate with MM risk and five of the 23 known MM risk loci associate with CLL risk. By integrating eQTL, Hi-C and ChIP-seq data, we show that these pleiotropic risk loci are enriched for B-cell regulatory elements and implicate B-cell developmental genes. These data identify shared biological pathways influencing the development of CLL and, MM and further our understanding of the aetiological basis of these B-cell malignancies.
- Open Access
- 31 March 2017
- Published by Springer Nature in Blood Cancer Journal
- Vol. 7 (3) , e549
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approaches are, therefore, required. A growing number of epigenetic inhibitors are now available including EZH2 inhibitors that are in early-stage clinical trials for treatment of haematological and other cancers with EZH2 mutations or in which overexpression has been correlated with poor outcomes. For the first time, we have identified and validated a robust and independent deleterious effect of high EZH2 expression on outcomes in myeloma patients. Using two chemically distinct small-molecule inhibitors, we demonstrate a reduction in myeloma cell proliferation with EZH2 inhibition, which leads to cell cycle arrest followed by apoptosis. This is mediated via upregulation of cyclin-dependent kinase inhibitors associated with removal of the inhibitory H3K27me3 mark at their gene loci. Our results suggest that EZH2 inhibition may be a potential therapeutic strategy for the treatment of myeloma and should be investigated in clinical studies.
- 31 March 2017
- Published by Springer Nature in Blood Cancer Journal
- Vol. 7 (3) , e549
Open AccessOverexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approaches are, therefore, required. A growing number of epigenetic inhibitors are now available including EZH2 inhibitors that are in early-stage clinical trials for treatment of haematological and other cancers with EZH2 mutations or in which overexpression has been correlated with poor outcomes. For the first time, we have identified and validated a robust and independent deleterious effect of high EZH2 expression on outcomes in myeloma patients. Using two chemically distinct small-molecule inhibitors, we demonstrate a reduction in myeloma cell proliferation with EZH2 inhibition, which leads to cell cycle arrest followed by apoptosis. This is mediated via upregulation of cyclin-dependent kinase inhibitors associated with removal of the inhibitory H3K27me3 mark at their gene loci. Our results suggest that EZH2 inhibition may be a potential therapeutic strategy for the treatment of myeloma and should be investigated in clinical studies.
- Open Access
- 24 November 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 13656
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression
Genome-wide association studies have identified several risk loci for multiple myeloma (MM); however, the mechanisms by which they influence MM are unknown. Here by using genetic association data and functional characterization, we demonstrate that rs4487645 G>T, the most highly associated variant (P = 5.30 × 10−25), resides in an enhancer element 47 kb upstream of the transcription start site of c-Myc-interacting CDCA7L. The G-risk allele, associated with increased CDCA7L expression (P=1.95 × 10−36), increases IRF4 binding and the enhancer interacts with the CDCA7L promoter. We show that suppression of CDCA7L limits MM proliferation through apoptosis, and increased CDCA7L expression is associated with adverse patient survival. These findings implicate IRF4-mediated CDCA7L expression in MM biology and indicate how germline variation might confer susceptibility to MM.
- 24 November 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 13656
Open AccessMultiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression
Genome-wide association studies have identified several risk loci for multiple myeloma (MM); however, the mechanisms by which they influence MM are unknown. Here by using genetic association data and functional characterization, we demonstrate that rs4487645 G>T, the most highly associated variant (P = 5.30 × 10−25), resides in an enhancer element 47 kb upstream of the transcription start site of c-Myc-interacting CDCA7L. The G-risk allele, associated with increased CDCA7L expression (P=1.95 × 10−36), increases IRF4 binding and the enhancer interacts with the CDCA7L promoter. We show that suppression of CDCA7L limits MM proliferation through apoptosis, and increased CDCA7L expression is associated with adverse patient survival. These findings implicate IRF4-mediated CDCA7L expression in MM biology and indicate how germline variation might confer susceptibility to MM.
- Open Access
- 12 June 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (6) , e99493
A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex
The chromosomal translocation t(4;14) deregulates MMSET (WHSC1/NSD2) expression and is a poor prognostic factor in multiple myeloma (MM). MMSET encodes two major protein isoforms. We have characterized the role of the shorter isoform (REIIBP) in myeloma cells and identified a clear and novel interaction of REIIBP with members of the SMN (survival of motor neuron) complex that directly affects the assembly of the spliceosomal ribonucleic particles. Using RNA-seq we show that REIIBP influences the RNA splicing pattern of the cell. This new discovery provides novel insights into the understanding of MM pathology, and potential new leads for therapeutic targeting.
- 12 June 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (6) , e99493
Open AccessA Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex
The chromosomal translocation t(4;14) deregulates MMSET (WHSC1/NSD2) expression and is a poor prognostic factor in multiple myeloma (MM). MMSET encodes two major protein isoforms. We have characterized the role of the shorter isoform (REIIBP) in myeloma cells and identified a clear and novel interaction of REIIBP with members of the SMN (survival of motor neuron) complex that directly affects the assembly of the spliceosomal ribonucleic particles. Using RNA-seq we show that REIIBP influences the RNA splicing pattern of the cell. This new discovery provides novel insights into the understanding of MM pathology, and potential new leads for therapeutic targeting.
- Open Access
- 1 October 2013
- Published by Elsevier in Cancer Letters
- Vol. 339 (1) , 49-59
Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress
- 1 October 2013
- Published by Elsevier in Cancer Letters
- Vol. 339 (1) , 49-59
Open AccessHsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress
- Open Access
- 2 July 2013
- Published by Springer Nature in Leukemia
- Vol. 28 (2) , 384-390
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
The mechanisms involved in the progression from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) to malignant multiple myeloma (MM) and plasma cell leukemia (PCL) are poorly understood but believed to involve the sequential acquisition of genetic hits. We performed exome and whole-genome sequencing on a series of MGUS (n=4), high-risk (HR)SMM (n=4), MM (n=26) and PCL (n=2) samples, including four cases who transformed from HR-SMM to MM, to determine the genetic factors that drive progression of disease. The pattern and number of non-synonymous mutations show that the MGUS disease stage is less genetically complex than MM, and HR-SMM is similar to presenting MM. Intraclonal heterogeneity is present at all stages and using cases of HR-SMM, which transformed to MM, we show that intraclonal heterogeneity is a typical feature of the disease. At the HR-SMM stage of disease, the majority of the genetic changes necessary to give rise to MM are already present. These data suggest that clonal progression is the key feature of transformation of HR-SMM to MM and as such the invasive clinically predominant clone typical of MM is already present at the SMM stage and would be amenable to therapeutic intervention at that stage.
- 2 July 2013
- Published by Springer Nature in Leukemia
- Vol. 28 (2) , 384-390
Open AccessIntraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
The mechanisms involved in the progression from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) to malignant multiple myeloma (MM) and plasma cell leukemia (PCL) are poorly understood but believed to involve the sequential acquisition of genetic hits. We performed exome and whole-genome sequencing on a series of MGUS (n=4), high-risk (HR)SMM (n=4), MM (n=26) and PCL (n=2) samples, including four cases who transformed from HR-SMM to MM, to determine the genetic factors that drive progression of disease. The pattern and number of non-synonymous mutations show that the MGUS disease stage is less genetically complex than MM, and HR-SMM is similar to presenting MM. Intraclonal heterogeneity is present at all stages and using cases of HR-SMM, which transformed to MM, we show that intraclonal heterogeneity is a typical feature of the disease. At the HR-SMM stage of disease, the majority of the genetic changes necessary to give rise to MM are already present. These data suggest that clonal progression is the key feature of transformation of HR-SMM to MM and as such the invasive clinically predominant clone typical of MM is already present at the SMM stage and would be amenable to therapeutic intervention at that stage.
- Open Access
- 30 May 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (3) , 348-359
Improved risk stratification in myeloma using a microRNA‐based classifier
Summary: Multiple myeloma (MM) is a heterogeneous disease. International Staging System/fluorescence hybridization (ISS/FISH)‐based model and gene expression profiles (GEP) are effective approaches to define clinical outcome, although yet to be improved. The discovery of a class of small non‐coding RNAs (micro RNAs, miRNAs) has revealed a new level of biological complexity underlying the regulation of gene expression. In this work, 163 presenting samples from MM patients were analysed by global miRNA profiling, and distinct miRNA expression characteristics in molecular subgroups with prognostic relevance (4p16, MAF and 11q13 translocations) were identified. Furthermore we developed an “outcome classifier”, based on the expression of two miRNAs (MIR17 and MIR886‐5p), which is able to stratify patients into three risk groups (median OS 19·4, 40·6 and 65·3 months, P = 0·001). The miRNA‐based classifier significantly improved the predictive power of the ISS/FISH approach (P = 0·0004), and was independent of GEP‐derived prognostic signatures (P < 0·002). Through integrative genomics analysis, we outlined the potential biological relevance of the miRNAs included in the classifier and their putative roles in regulating a large number of genes involved in MM biology. This is the first report showing that miRNAs can be built into molecular diagnostic strategies for risk stratification in MM.
- 30 May 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (3) , 348-359
Open AccessImproved risk stratification in myeloma using a microRNA‐based classifier
Summary: Multiple myeloma (MM) is a heterogeneous disease. International Staging System/fluorescence hybridization (ISS/FISH)‐based model and gene expression profiles (GEP) are effective approaches to define clinical outcome, although yet to be improved. The discovery of a class of small non‐coding RNAs (micro RNAs, miRNAs) has revealed a new level of biological complexity underlying the regulation of gene expression. In this work, 163 presenting samples from MM patients were analysed by global miRNA profiling, and distinct miRNA expression characteristics in molecular subgroups with prognostic relevance (4p16, MAF and 11q13 translocations) were identified. Furthermore we developed an “outcome classifier”, based on the expression of two miRNAs (MIR17 and MIR886‐5p), which is able to stratify patients into three risk groups (median OS 19·4, 40·6 and 65·3 months, P = 0·001). The miRNA‐based classifier significantly improved the predictive power of the ISS/FISH approach (P = 0·0004), and was independent of GEP‐derived prognostic signatures (P < 0·002). Through integrative genomics analysis, we outlined the potential biological relevance of the miRNAs included in the classifier and their putative roles in regulating a large number of genes involved in MM biology. This is the first report showing that miRNAs can be built into molecular diagnostic strategies for risk stratification in MM.
- Open Access
- 14 May 2013
- Published by Springer Nature in Leukemia
- Vol. 27 (12) , 2397-2403
Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
- 14 May 2013
- Published by Springer Nature in Leukemia
- Vol. 27 (12) , 2397-2403
Open AccessUnderstanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
- Open Access
- 3 May 2013
- Published by Springer Nature in Blood Cancer Journal
- Vol. 3 (5) , e114
MMSET is the key molecular target in t(4;14) myeloma
- 3 May 2013
- Published by Springer Nature in Blood Cancer Journal
- Vol. 3 (5) , e114
Open AccessMMSET is the key molecular target in t(4;14) myeloma